Sinomab Bioscience News Today : Breaking News, Live Updates & Top Stories | Vimarsana

<p>HONG KONG SAR - <a href="https://www.media-outreach.com/">Media OutReach</a> - 26 April 2023 - A Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases - <b>SinoMab BioScience Limited (Stock Code: 3681.HK, "SinoMab" or the "Company")</b>, is pleased to announce that Phase III clinical trial of SinoMab's flagship product SM03 (Suciraslimab) for rheumatoid arthritis (RA) in China (Study No.</p>

HONG KONG, Dec 19, 2022 - (ACN Newswire) - SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, is pleased to announce that the Company was awarded the "Most Valuable Pharmaceutical and...

SinoMab appoints new President

HONG KONG, Nov 4, 2022 - (ACN Newswire) - SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-based biopharmaceutical

Everest Medicines has received approval for a phase 1b study of EVER001 for the treatment of glomerular diseases.